Clinical Trial Detail

NCT ID NCT02400255
Title Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Arog Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

Crenolanib

Age Groups: adult senior

Additional content available in CKB BOOST